1.
Reich K, Papp K, Blauvelt A, Langley R, Armstrong A, Warren R, Gordon K, Merola J, Madden C, Wang M, Vanvoorden V, Lebwohl M. Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study. J of Skin [Internet]. 2020Oct.27 [cited 2021Jan.25];4(6):s82. Available from: https://jofskin.org/index.php/skin/article/view/1115